Table 1.
DUB inhibitors
| Compound | Reported activity/target | Ref. |
|---|---|---|
| Inhibitors containing Michael acceptors | ||
| 12Δ-PGJ2 | UCHL3 | [139] |
| 15Δ-PGJ2 | UCHL1 | [139] |
| G5 | Broad spectrum DUB inhibition | [140] |
| b-AP15 | USP14/UCH37 | [141] |
| VLX1570 | USP14/UCH37 | [141] |
| AM146, RA-9 and RA-14 | USP2a/USP2b/USP5/USP8 | [143] |
| WP1130 | USP5/USP9x/USP14/UCHL1/UCHL5 | [144] |
| Eeyarestatin 1 | Ataxin-3 | [145] |
| Small inhibitors | ||
| AC17 | USP14/UCH37 | [142] |
| P022077 | USP7 | [146] |
| HBX 41, 108 | USP7 | [148] |
| HBX-19, 818 | USP7 | [149] |
| HBX-28, 258 | USP7 | [149] |
| P5091 | USP7 | [147] |
| Cpd 14 | USP7/USP47 | [150] |
| P22077 | USP7/USP47 | [151] |
| IU1 | USP14 | [139] |
| LDN-57444 | UCHL1 | [152] |
| LDN91946 | UCHL1 | [153] |
| LS1 | UCHL3 | [156] |
| PR-619 | Broad spectrum DUB inhibition | [157] |
| 15-oxospiramilactone (S3) | USP30 | [158] |
| Clinical drugs | ||
| Pimozide | USP1 | [154] |
| Auranofin | proteasome-associated DUBs | [155] |